LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines

R Moosavi*, F Bremner, J Acheson
University of Torino – Department of Surgical Sciences – Eye Clinic, Via Juvarra 19 – 10121 – Torino, Italy
Department of Neuro-ophthalmology, National Hospital of Neurology and Neurosurgery, Queen’s Square, London, UK

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 2342
Abstract HTML Views: 1925
PDF Downloads: 671
Total Views/Downloads: 4938
Unique Statistics:

Full-Text HTML Views: 1231
Abstract HTML Views: 1100
PDF Downloads: 399
Total Views/Downloads: 2730

Creative Commons License
© Moosavi et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Neuro-ophthalmology, National Hospital of Neurosurgery and Neurology, Queen’s Square, London, UK; Tel: 0203 448 3382; Fax: 0203 448 4339; E-mail:


We report adherence to United Kingdom national guidelines on surveillance for Fingolimod associated macular oedema (FAME) and the impact on clinical services at our unit. We conducted a 9-month study, measuring referral interval, visual function and performing OCT scans for all patients referred for FAME surveillance. 38 patients in total were seen, representing 9% of all new ophthalmic referrals during the study period. 26% were seen between 2 and 4 months after starting Fingolimod treatment, 74% between 3 and 4 months after starting Fingolimod treatment. The impact on clinical services is discussed.

Keywords: Fingolimod, guidelines, macular oedema, screening.